- In April 2023, Aimmune Therapeutics, Inc. (Nestle Health Science), a leading company in food allergy treatments, announced positive real-world data from its oral immunotherapy product, demonstrating sustained desensitization in a larger patient population than clinical trials. This data supports the long-term effectiveness of their therapy
- In March 2023, DBV Technologies, a clinical-stage biopharmaceutical company, reported progress in its Phase 3 clinical trial for a novel epicutaneous (patch) immunotherapy for peanut allergy, signaling potential for a non-oral treatment option. This advancement aims to provide an alternative for patients unable to tolerate oral therapies
- In March 2023, Sanofi and Regeneron Pharmaceuticals, Inc., collaborating partners, announced the initiation of a new Phase 3 study investigating their biologic drug (Omalizumab) for broader use in multiple food allergies, including peanut, following previous successes in chronic spontaneous urticaria and asthma. This expansion broadens the potential application of their existing drug
- In February 2023, Kaléo, Inc., a privately held pharmaceutical company, introduced an updated version of its epinephrine autoinjector with enhanced user features and connectivity options to improve patient compliance and emergency response. This innovation aims to make emergency treatment more accessible and user-friendly
- In January 2023, Camallergy, a U.K.-based biopharmaceutical company, presented preclinical data for a new rapid oral immunotherapy formulation for peanut allergy, demonstrating promising results in accelerating desensitization with fewer treatment sessions. This development could lead to faster and more convenient treatment regimens
